(Q35205524)

7 August 2017

title

The importance of molecular monitoring in acute promyelocytic leukaemia (English)

1 reference

7 August 2017

1 reference

2

Massimo Breccia

1 reference

7 August 2017

1

Francesco Lo-Coco

1 reference

7 August 2017

Daniela Diverio

3

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Best Practice and Research: Clinical Haematology

7 August 2017

published in

1 reference

7 August 2017

volume

16

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

503-520

1 reference

Acute promyelocytic leukemia: from clinic to molecular biology

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Pathogenesis and management of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Acute promyelocytic leukemia: a curable disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Acute promyelocytic leukemia: evolving therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

A variant form of hypergranular promyelocytic leukaemia (M3)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Quantification of PML-RARalpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Antibody therapy for residual disease in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900041-0

7 January 2021

10.1016/S1521-6926(03)00041-0

Identifiers

DOI

1 reference

7 August 2017

1 reference